Inhibikase Therapeutics (IKT) Competitors $1.94 -0.04 (-2.02%) (As of 12:50 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends IKT vs. BLUE, ENTX, CRTX, DTIL, JATT, TARA, DBVT, OMGA, ACHL, and DYAIShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include bluebird bio (BLUE), Entera Bio (ENTX), Cortexyme (CRTX), Precision BioSciences (DTIL), JATT Acquisition (JATT), Protara Therapeutics (TARA), DBV Technologies (DBVT), Omega Therapeutics (OMGA), Achilles Therapeutics (ACHL), and Dyadic International (DYAI). These companies are all part of the "medical" sector. Inhibikase Therapeutics vs. bluebird bio Entera Bio Cortexyme Precision BioSciences JATT Acquisition Protara Therapeutics DBV Technologies Omega Therapeutics Achilles Therapeutics Dyadic International bluebird bio (NASDAQ:BLUE) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations. Which has more volatility and risk, BLUE or IKT? bluebird bio has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Which has better valuation & earnings, BLUE or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than bluebird bio. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$29.50M1.94-$211.91M-$1.87-0.16Inhibikase Therapeutics$260K55.67-$19.03M-$2.67-0.73 Do institutionals & insiders have more ownership in BLUE or IKT? 87.4% of bluebird bio shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 1.4% of bluebird bio shares are held by insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer BLUE or IKT? In the previous week, bluebird bio had 17 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 21 mentions for bluebird bio and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.88 beat bluebird bio's score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bluebird bio 1 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BLUE or IKT more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. bluebird bio's return on equity of -322.46% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% Inhibikase Therapeutics N/A -350.63%-201.82% Does the MarketBeat Community prefer BLUE or IKT? bluebird bio received 1030 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 90.00% of users gave Inhibikase Therapeutics an outperform vote while only 71.16% of users gave bluebird bio an outperform vote. CompanyUnderperformOutperformbluebird bioOutperform Votes103971.16% Underperform Votes42128.84% Inhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% Do analysts recommend BLUE or IKT? bluebird bio currently has a consensus price target of $3.03, indicating a potential upside of 925.42%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 235.03%. Given bluebird bio's higher possible upside, equities research analysts clearly believe bluebird bio is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Summarybluebird bio beats Inhibikase Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$14.47M$2.98B$5.09B$20.10BDividend YieldN/A1.91%5.04%3.49%P/E Ratio-0.7318.9994.6037.65Price / Sales55.67286.511,217.5218.50Price / CashN/A169.3839.4921.28Price / Book-27.724.416.954.64Net Income-$19.03M-$41.63M$118.83M$985.06M7 Day Performance-17.79%-4.44%-1.52%1.43%1 Month Performance-12.61%-6.19%-3.39%2.09%1 Year Performance106.39%26.61%32.17%26.15% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics2.7555 of 5 stars$1.94-2.0%$6.50+235.0%+130.1%$14.47M$260,000.00-0.738BLUEbluebird bio2.4743 of 5 stars$0.30-2.6%$3.03+925.4%-92.1%$57.36M$29.50M-0.16323Analyst ForecastGap UpENTXEntera Bio2.0488 of 5 stars$1.59+2.5%$10.00+529.4%+112.3%$56.85M$130,000.00-6.0820CRTXCortexymeN/A$1.84+4.0%N/A+101.1%$55.48MN/A-0.6255DTILPrecision BioSciences4.1256 of 5 stars$6.80-5.3%$39.50+480.9%-46.6%$52.16M$48.73M119.69200JATTJATT AcquisitionN/A$2.90-7.9%N/A-29.5%$50.03MN/A0.003High Trading VolumeTARAProtara Therapeutics2.1629 of 5 stars$2.34+1.3%$24.00+925.6%+102.6%$48.27MN/A0.0030Analyst RevisionDBVTDBV Technologies3.275 of 5 stars$0.50-1.8%$6.00+1,102.4%-70.2%$48.15M$15.73M0.00106Stock SplitGap UpOMGAOmega Therapeutics1.4796 of 5 stars$0.82+3.4%$9.20+1,026.2%-60.5%$45.23M$3.09M-0.59120ACHLAchilles Therapeutics2.8001 of 5 stars$1.06-0.9%$4.00+277.4%+32.1%$43.57MN/A0.00250DYAIDyadic International2.132 of 5 stars$1.42-4.7%$6.00+322.5%-17.7%$42.02M$2.90M-5.657Analyst Revision Related Companies and Tools Related Companies BLUE Alternatives ENTX Alternatives CRTX Alternatives DTIL Alternatives JATT Alternatives TARA Alternatives DBVT Alternatives OMGA Alternatives ACHL Alternatives DYAI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IKT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts